Astellas Pharma Inc (ALPMY) Unsp ADR Each Repr 0.25 Share

Sell:$9.65Buy:$9.65$0.01 (0.14%)

Prices delayed by at least 15 minutes
Sell:$9.65
Buy:$9.65
Change:$0.01 (0.14%)
Deal now
Prices delayed by at least 15 minutes
Sell:$9.65
Buy:$9.65
Change:$0.01 (0.14%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Key people

Kenji Yasukawa
Chairman of the Board, Chairman of the board of Directors, Representative Director
Naoki Okamura
President, Chief Executive Officer, Representative Director
Atsushi Kitamura
Chief Financial Officer, Senior Managing Executive Officer
Yoshitsugu Shitaka
Senior Managing Executive Officer, Chief Scientific Officer
Katsuyoshi Sugita
Vice President, Representative Director
Catherine Levitt
General Counsel
Hideki Shima
Senior Managing Executive Officer, Chief Manufacturing Officer
Tadaaki Taniguchi
Senior Managing Executive Officer, Chief Medical Officer
Jun Kono
Managing Executive Officer, Head of Japan Commercial
Yuusuke Kumagai
Executive Officer, Director of External Affairs
Rika Hirota
Director
Rie Akiyama
Independent Director
Tomoko Aramaki
Independent Director
Masahiro Miyazaki
Independent Director
Mika Nakayama
Independent Director
Click to see more

Key facts

  • EPIC
    4503
  • Location
    Japan
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US04623U1025
  • Market cap
    $0.00
  • Employees
    14,754
  • Shares in issue
    1.81bn
  • Exchange
    Tokyo Stock Exchange
  • Index
    Nikkei 225 Index, TOPIX Stock Price Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.